NovaBridge Biosciences
NASDAQ:NBPBiotechnology
-$0.07 today
- Market cap
- $104.10M
- Beta
- 1.48
- P/E (TTM)
- -25.5
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.90M
NBP Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
NovaBridge BiosciencesNASDAQ: NBP
Financing Cash Flow · Q4 FY2025 · quarter ended Dec 2025
Financing cash flow turns negative
Q4 FY2025 financing cash flow was -$3.02M, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $433.38M. Over 3 fiscal years it compounded at +10.9% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near -$3.02M or moves back toward the trailing-twelve-month quarterly average of $108.35M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
Mixed currencies · from the cash flow
- Latest · FY2025
- 57.73M USD
- Year-over-year change
- —
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 57.73M | — |
| FY2024 | 2024-12-31 | (2.44M) | +70.4% |
| FY2023 | 2023-12-31 | (8.25M) | -119.5% |
| FY2022 | 2022-12-31 | 42.36M | -92.9% |
| FY2021 | 2021-12-31 | 593.92M | — |
Financing Cash Flow vs competitors
How NBP compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Over three fiscal years its annual growth of +10.9% compares with a peer median of -4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥433.38M CNY | — | +10.9% | — |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $396.39M USD | — | +136.2% | — |
| LTM Mar 2026 | $251.49M USD | +466.1% | +53.9% | 698594.4% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $143.06M USD | +136.8% | -62.1% | — |
| LTM Mar 2026 | $141.69M USD | +10.0% | -4.0% | — | |
| LTM Mar 2026 | $77.36M USD | +5279.6% | -6.9% | — | |
| LTM Dec 2025 | $45.77M USD | — | -22.1% | — | |
| LTM Mar 2026 | $45.65M USD | +8746.7% | +378.4% | — | |
| LTM Mar 2026 | $44.68M USD | +269.7% | — | — | |
| LTM Mar 2026 | $26.73M USD | +25.9% | +38.3% | — | |
| LTM Mar 2026 | $155K USD | -99.9% | -90.2% | — | |
| Peer median (excluding NBP) | — | +203.3% | -4.0% | 698594.4% | |
Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · CNY | FY2022 Dec 2022 · CNY | FY2023 Dec 2023 · CNY | FY2024 Dec 2024 · CNY | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (2.33B) | (2.51B) | (208.18M) | (362.72M) | (88.34M) |
| Depreciation & Amortization | 34.14M | 63.82M | 1.06M | 7.14M | 856K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 608.61M | 357.15M | 10.26M | (14.23M) | 5.97M |
| Change in Working Capital | 394.52M | 552.06M | (37.2M) | (20.52M) | 17.07M |
| Accounts Receivables | 97.42M | 33.08M | 0 | 0 | 0 |
| Inventory | (27.24M) | 27.24M | 0 | 0 | 0 |
| Accounts Payables | 107.85M | 0 | 0 | 0 | 0 |
| Other Working Capital | 216.49M | 491.75M | (37.2M) | (20.52M) | 17.07M |
| Other Non-Cash Items | 321.18M | 431.48M | 161.2M | 5.9M | 43.84M |
| Operating Cash Flow | (973.09M) | (1.1B) | (72.85M) | (384.42M) | (20.6M) |
| Capital Expenditures | (29.93M) | (45.83M) | (164.35K) | (350.34K) | (7K) |
| Acquisitions (Net) | (6M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (10.17B) | (7.41B) | 0 | (1.79B) | (49.96M) |
| Sales of Investments | 9.48B | 7.91B | 0 | 801.66M | 154.89M |
| Other Investing Activities | 0 | 26K | (107.47M) | 452.53K | 47K |
| Investing Cash Flow | (727.21M) | 458.38M | (107.63M) | (992.42M) | 104.97M |
| Debt Repayment | 0 | 2.75M | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 61.91M |
| Common Stock Repurchased | 0 | (3.08M) | (8.66M) | (2.45M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 593.92M | 60.86M | 407.88K | 0 | (4.19M) |
| Financing Cash Flow | 593.92M | 42.36M | (8.25M) | (2.44M) | 57.73M |
| Effect of Forex Changes | (128.77M) | 389.2M | 36.89M | (327.04M) | 276K |
| Net Change in Cash | (1.24B) | (212.86M) | (151.58M) | (1.71B) | 142.37M |
| Free Cash Flow | (1B) | (1.15B) | (73.02M) | (384.77M) | (20.6M) |
NovaBridge Biosciences
NASDAQ:NBP
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.